| Literature DB >> 35988096 |
Pietro Bertoglio1, Vittorio Aprile2, Luigi Ventura3,4, Maria Cattoni5, Dania Nachira6, Filippo Lococo6, Maria Rodriguez Perez7, Francesco Guerrera8, Fabrizio Minervini9, Giulia Querzoli10, Giovanni Bocchialini3, Diana Bacchin11, Francesca Franzi12, Guido Rindi13, Salvatore Bellafiore14, Federico Femia8, Giuseppe Salvatore Bogina10, Piergiorgio Solli1, Peter Kestenholz9, Enrico Ruffini8, Massimiliano Paci15, Stefano Margaritora6, Andrea Selenito Imperatori5, Marco Lucchi11, Letizia Gnetti16, Alberto Claudio Terzi17.
Abstract
OBJECTIVE: The presence of micropapillary and solid adenocarcinoma patterns leads to a worse survival and a significantly higher tendency to recur. This study aims to assess the impact of pT descriptor combined with the presence of high-grade components on long-term outcomes in early-stage lung adenocarcinomas.Entities:
Keywords: Adenocarcinoma subtypes; Lung adenocarcinoma; Lung cancer; TNM staging
Mesh:
Year: 2022 PMID: 35988096 PMCID: PMC9526683 DOI: 10.1007/s00408-022-00561-y
Source DB: PubMed Journal: Lung ISSN: 0341-2040 Impact factor: 3.777
Preoperative, intraoperative, and postoperative features of patients of the whole cohort and of the groups with or without high-grade component
| Variable | All the cohort (607) | Non-high-grade (377) | High-grade (230) | |
|---|---|---|---|---|
| Sex | 0.075 | |||
| Male | 331 (54.5) | 195 (51.7) | 136 (59.1) | |
| Age at diagnosis in years (mean, range) | 68.2 (41–91) | 68.5 (42–91) | 67.8 (41–84) | 0.338 |
| Smoking status | ||||
| Never | 139 (22.9) | 99 (26.2) | 40 (17.4) | |
| Former | 269 (44.3) | 172 (45.6) | 97 (42.2) | |
| Active | 172 (28.3) | 92 (24.4) | 80 (34.8) | |
| Respiratory comorbidities n (%) | 0.712 | |||
| Yes | 158 (26) | 96 (25.5) | 62 (26.9) | |
| Cardiovascular comorbidities | 0.763 | |||
| Yes | 365 (60.1) | 228 (60.5) | 137 (59.6) | |
| ASA score | 0.466 | |||
| 1 | 83 (13.7) | 56 (14.8) | 27 (11.7) | |
| 2 | 316 (52.1) | 200 (53.0) | 116 (50.4) | |
| 3 | 162 (26.7) | 95 (25.2) | 67 (29.1) | |
| 4 | 15 (2.5) | 9 (2.4) | 6 (2.6) | |
| FEV1% (mean, ± SD) | 95.7 ± 21.6 | 96.7 ± 21.7 | 94.2 ± 21.3 | 0.226 |
| DLCO % (mean, ± SD) | 74.2 ± 28.7 | 72.2 ± 27.8 | 77.6 ± 29.9 | 0.123 |
| Side | 0.499 | |||
| Right | 359 (59.1) | 219 (58.1) | 140 (60.8) | |
| Type of resection | 0.135 | |||
| Sublobar | 114 (18.7) | 65 (17.2) | 49 (21.3) | |
| Wedge resection | 44 (7.2) | 23 (6.1) | 21 (9.1) | |
| Anatomic segmentectomy | 79 (13.0) | 49 (12.9) | 30 (13.0) | |
| Lobectomy | 469 (77.3) | 301 (79.8) | 168 (73.0) | |
| Other | 15 (2.4) | 15 (2.4) | 11 (4.8) | |
| Lobectomy plus wedge resection | 5 (0.8) | 1 (0.3) | 4 (1.8) | |
| Bilobectomy | 5 (0.8) | 0 (0.0) | 5(2.2) | |
| Pneumonectomy | 5 (0.8) | 3 (0.8) | 2 (0.9) | |
| Surgical technique | ||||
| Open | 347 (57.2) | 194 (51.4) | 153 (66.5) | |
| VATS | 222(36.6) | 150 (39.8) | 72 (31.3) | |
| Robotic | 38 (6.3) | 33 (8.7) | 5 (2.2) | |
| High-grade pattern | ||||
| Yes | 230 (37.9) | |||
| Micropapillary | 75 (12.4) | |||
| Solid | 169 (27.8) | |||
| Lymphovascular invasion | 0.056 | |||
| Present | 95 (15.7) | 47 (12.5) | 48 (20.8) | |
| Visceral pleural invasion | ||||
| Present | 186 (30.6) | 98 (26.0) | 88 (38.3) | |
| Size of the tumor mm (mean ± SD) | 23.6 ± 12.9 | 23.0 ± 12.7 | 24.7 ± 13.3 | 0.128 |
| pT | ||||
| pT1 | 326 (53.7) | 224 (59.4) | 102 (44.3) | |
| pT1a | 64 (10.5) | 41 (10.9) | 23 (10.0) | |
| pT1b | 163 (26.9) | 116 (30.8) | 47 (20.4) | |
| pT1c | 99 (16.3) | 67 (17.8) | 32 (13.9) | |
| pT2 | 233 (38.4) | 124 (32.9) | 109 (47.4) | |
| pT2a | 195 (32.1) | 105 (27.8) | 90 (39.1) | |
| pT2b | 38 (6.3) | 19 (5.0) | 19 (8.3) | |
| pT3 | 48 (7.9) | 29 (7.7) | 19 (8.3) | |
Bold values indicate statistical significance
ASA American Society of Anesthesiologists, FEV1 Forced Expiratory Volume in the first second, DLCO Diffusion Lung Carbon Monoxide, VATS Video-Assisted Thoracic Surgery, SD Standard Deviation
Fig. 1a Overall Survival of T1a-b-c non-high-grade and T1a-b-c high-grade in the whole cohort. Confidence interval: 95%; b Disease-Free Survival of T1a-b-c non-high-grade and T1a-b-c high-grade in the whole cohort. CI 95%
Fig. 2a Overall Survival of T2a non-high-grade and T1a-b-c high-grade in the whole cohort; b Disease-Free Survival of T2a non-high-grade and T1a-b-c high-grade in the whole cohort. CI 95%
Fig. 3a Overall Survival of T2a-b non-high-grade and T2a-b high-grade in the whole cohort; b Disease-Free Survival of T2a-b non-high-grade and T2a-b high-grade in the whole cohort. CI 95%
Fig. 4a Overall Survival of T3 non-high-grade and T3 high-grade in the whole cohort; b Disease-Free Survival of T3 non-high-grade and T3 high-grade in the whole cohort. CI 95%
Univariate and multivariable analysis of the whole cohort
| OS | DFS | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariable | Univariate | Multivariable | |||||
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | |||||
| Age (continuous variable) | ||||||||
| Male sex (vs female) | 2.419 (1.497–3.910) | 1.388 (0.984–1.958) | 1.251 (0.885–1.769) | |||||
| Smoking habit (current or former vs never) | 1.094 (0.813–1.473) | 1.027 (0.815–1.295) | ||||||
| Lobectomy (vs other intervention) | 0.958 (0.579–1.584) | 0.803 (0.547–1.180) | ||||||
| Minimally invasive surgery (vs open surgery) | 0.679 (0.441–1.046) | 0.650 (0.387–1.092) | 0.719 (0.503–1.028) | 0.780 (0.543–1.120) | ||||
| Lymphovascular invasion (vs no) | 0.983 (0.495–1.951) | 1.019 (0.631–1.648) | ||||||
| Pleural invasion (vs no) | 1.263 (0.811–1.965) | 1.167 (0.817–1.666) | ||||||
| pT according to high-grade pattern | ||||||||
Bold values indicate statistical significance
OS Overall Survival, DFS Disease-Free Survival, HR Hazard Ratio, CI Confidence Interval
Preoperative, intraoperative, and postoperative features of patients after the propensity score matching and of the subgroups with or without high-grade component
| Variable | All the cohort (460) | Non-high-grade (230) | High-grade (230) | |
|---|---|---|---|---|
| Sex | 0.924 | |||
| Male | 271 (59.1) | 135 (58.7) | 136 (59.1) | |
| Age at diagnosis in years (mean, range) | 68.1 (41–87) | 68.4 (42–87) | 67.8 (41–84) | 0.446 |
| Smoking status | 0.129 | |||
| Never | 97 (21.2) | 57 (24.8) | 40 (17.4) | |
| Former | 193 (42.0) | 97 (42.2) | 97 (42.2) | |
| Active | 148 (32.2) | 67 (29.1) | 80 (34.8) | |
| Respiratory comorbidities | 0.635 | |||
| Yes | 128 (27.8) | 66 (28.7) | 62 (26.9) | |
| Cardiovascular comorbidities | 0.909 | |||
| Yes | 274 (59.6) | 137 (59.6) | 137 (59.6) | |
| ASA score | 0.551 | |||
| 1 | 59 (12.8) | 32 (13.9) | 27 (11.7) | |
| 2 | 239 (52.0) | 123 (53.5) | 116 (50.4) | |
| 3 | 125 (27.2) | 57 (24.8) | 67 (29.1) | |
| 4 | 10 (2.2) | 4 (1.7) | 6 (2.6) | |
| FEV1% (mean ± SD) | 95.4 ± 21.8 | 96.6 ± 22.2 | 94.2 ± 21.3 | 0.303 |
| DLCO % (mean ± SD) | 75.0 ± 28.7 | 72.7 ± 27.3 | 77.6 ± 29.9 | 0.227 |
| Side | 0.775 | |||
| Right | 278 (60.4) | 137 (59.6) | 140 (60.8) | |
| Type of resection | 0.164 | |||
| Sublobar | 91 (19.8) | 42 (18.3) | 49 (21.3) | |
| Wedge resection | 35 (7.6) | 14 (6.1) | 21 (9.1) | |
| Anatomic segmentectomy | 62 (13.5) | 32 (13.9) | 30 (13.0) | |
| Lobectomy | 349 (75.9) | 181 (78.7) | 168 (73.0) | |
| Other | 14 (3.) | 3 (1.3) | 11 (4.8) | |
| Lobectomy plus wedge resection | 5 (1.1) | 1 (0.4) | 4 (1.8) | |
| Bilobectomy | 5 (1.1) | 0 (0.0) | 5 (2.2) | |
| Pneumonectomy | 4 (0.9) | 2 (0.9) | 2 (0.9) | |
| Surgical technique | 0.099 | |||
| Open | 305 (66.3) | 151 (65.6) | 153 (66.5) | |
| VATS | 136 (29.6) | 65 (28.3) | 72 (31.3) | |
| Robotic | 19 (4.1) | 14 (6.1) | 5 (2.2) | |
| High-grade pattern | n.a | |||
| Yes | 230 (50.0) | 0 | 230 (50.0) | |
| Micropapillary | 75 (16.3) | 75 (16.3) | ||
| Solid | 169 (36.7) | 169 (36.7) | ||
| Lymphovascular invasion | 0.226 | |||
| Present | 77 (16.7) | 31 (13.5) | 48 (20.8) | |
| Visceral pleural invasion | 0.071 | |||
| Present | 158 (34.3) | 70 (30.4) | 88 (38.3) | |
| Size of the tumor mm (mean ± SD) | 24.7 ± 13.5 | 24.7 ± 13.8 | 24.7 ± 13.3 | 0.961 |
| pT | 0.426 | |||
| pT1 | 220 (47.9) | 117 (50.9) | 102 (44.3) | |
| pT1a | 45 (9.8) | 21 (9.1) | 23 (10.0) | |
| pT1b | 102 (22.2) | 57 (24.8) | 47 (20.4) | |
| pT1c | 72 (15.7) | 39 (16.9) | 32 (13.9) | |
| pT2 | 198 (43.3) | 89 (38.7) | 109 (47.4) | |
| pT2a | 167 (36.3) | 77 (33.5) | 90 (39.1) | |
| pT2b | 31 (6.7) | 12 (5.2) | 19 (8.3) | |
| pT3 | 43 (9.3) | 24 (10.4) | 19 (8.3) |
ASA American Society of Anesthesiologists, FEV1 Forced Expiratory Volume in the first second, DLCO Diffusion Lung Carbon Monoxide, VATS Video-Assisted Thoracic Surgery, SD Standard Deviation, n.a. not applicable
Fig. 5a Overall Survival of T1a-b-c non-high-grade and T1a-b-c high-grade in the matched cohort; b Disease-Free Survival of T1a-b-c non-high-grade and T1a-b-c high-grade in the matched cohort. CI 95%
Univariate and Multivariable analysis of the cohort obtained after Propensity Score Match
| OS | DFS | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariable | Univariate | Multivariable | |||||
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | |||||
| Age (continuous variable) | ||||||||
| Male sex | 1.336 (0.900–1.981) | |||||||
| Smoking habit (current or former vs never) | 1.019 (0.748–1.389) | 0.982 (0.765–1.262) | ||||||
| Lobectomy (vs other intervention) | 0.959 (0.569–1.615) | 0.874 (0.572–1.333) | ||||||
| Minimally invasive surgery (vs open surgery) | 0.622 (0.352–1.101) | 0.702 (0.394–1.249) | 0.702 (0.459–1.072) | 0.785 (0.512–1.205) | ||||
| Lymphovascular invasion (vs no) | 0.904 (0.439–1.862) | 0.853 (0.494–1.473) | ||||||
| Pleural invasion (vs no) | 1.310 (0.825–2.079) | 1.219 (0.831–1.790) | ||||||
| pT according to high-grade pattern | ||||||||
Bold values indicate statistical significance
OS Overall Survival, DFS Disease-Free Survival, HR Hazard Ratio, CI Confidence Interval